Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition

Journal of Hypertension, Supplement

Volumn 15, Issue 5, 1997, Pages

  Bühler, Fritz R ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Calcium T channel antagonist; Cardiovascular care; Sympathetic system

Indexed keywords

1,4 DIHYDROPYRIDINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL; DILTIAZEM; MIBEFRADIL; PERIPHERAL VASODILATING AGENT; VERAPAMIL;

ADRENERGIC SYSTEM; ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; HEART FAILURE; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; PACEMAKER; PRIORITY JOURNAL; PURKINJE FIBER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER;

ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; REFLEX; SYMPATHETIC NERVOUS SYSTEM;

EID: 0031437326     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA: Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
2. Palatini P, Julius S: Heart rate and cardiovascular risk. J Hypertens 1997, 15:3-17.
3. Habib G: Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther 1997, 19:39-52.
4. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta-blockade during and after myocardial infarction; an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
5. Lonn E, Yusuf S, Prabhat J, et al.: Emergency role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1995, 92:1326-1331.
6. Bühler FR: Antihypertensive care with calcium antagonists. In Hypertension, Pathophysiology, Diagnosis and Management, 2nd edn. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2801-2814.
7. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT II) and other recent studies. Am J Cardiol 1991, 67:1295-1297.
8. Opie LH, Messerli FH: Nifedipine and mortality: grave defects in the dossler. Circulation 1995, 92:1068-1073.
9. World Health Organization - International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens (in press).
10. Opie LH, Bühler FR, Fleckenstein A, et al.: International Society and Federation of Cardiology: Working Group on Classification of Calcium Antagonists for Cardiovascular Disease. Am J Cardiol 1987, 60:630-632.
11. Clozel JP, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischaemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989, 14:713-721.
12. Véniant M, Clozel JP, Hess P, Wolfgang R: Haemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991, 18 (suppl 19):S55-S58.
13. 2+ channels by Ro 40-5967. Circ Res 1994, 75:144-148.
14. 2+ channel antagonists. Trends Pharmacol Sci 1992, 131:256-262.
15. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994, 75:149-155.
16. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993, 73:777-782.
17. Kannel WB, Gordon T, Lastelli WP, et al.: Electrographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1970, 72:813-825.
18. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996, 275:1507-1513.
19. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5:95-110.
20. Höglund C, Pordy R, Watt A, et al.: A comparison of the effects of mibefradil and atenolol on left ventricular hypertrophy regression in hypertensive patients. Am J Cardiol (in press).
21. Catapano AL: Calcium antagonists and atherosclerosis: experimental evidence. Eur Heart J 1997, 18 (suppl A):A80-A86.
22. Schmitt R, Clozel J-P, Iberg N, Bühler FR: Mibefradil prevents neointimal formation after vascular injury in rats: possible role of the blockade of the T-type voltage operated calcium channel. Arterioscler Thromb Vasc Biol 1995, 15:1161-1165.
23. Hahn AWA, Kern F, Jonas U, John M, Bühler FR, Resink TJ: Functional aspects of vascular tenascin-C expression. J Vasc Res 1995, 32:162-174.
24. Lafleur DE, Fagin JA, Forrester S, Rubin SA, Sharifi BG: Cloning and characterisation of alternatively spliced isoforms of rat tenascin: platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem 1994, 269:20757-20763.
25. Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785-791.
26. Kiowski W, Erne P, Bertel O, Bolli P, Bühler FR: Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J Am Coll Cardiol 1986, 7:344-348.
27. Noll G, Wenzel RR, Allegranza G, Lüscher TF: Nifedipine activates sympathetic nervous system: additive effects of cold pressor test [abstract]. Eur Heart J 1994, 15 (suppl 15):190.
28. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting antagonists. In Hypertension, Diagnosis, and Management, 2nd edn. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2815-2825.
29. Schmitt R, Kleinbloesem C, Belz G, et al.: Haemodynamic and humoral effects of the novel calcium antagonist Ro 40-5976 in patients with hypertension. Clin Pharmacol Ther 1992, 52:314-323.
30. Wagner C, Krämer B, Kurtz A: T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol (in press).
31. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996, 27:426-432.
32. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist mibefradil (Ro 40-5967), on silent ischaemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996, 26:317-322.
33. Furberg CD, Psaty BM, Meyer JV: Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331.
34. Psaty BM, Heckbert SR, Koepsell TD, et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
35. Pahor M, Guralnik JM, Conti M, et al.: Long-term survival and use of antihypertensive medication in older persons. J Am Geriat Soc 1995, 43:1191-1197.
36. Alderman MH, Cohen H, Rogué R, Madhavan S: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997, 349:594-598.
37. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997, 350:757-763.
38. Leenen FHH, Holliwell DL: Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992, 69:639-645.
39. Ruzicka M, Leenen FHH: Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996, 9:86-94.
40. Bellet M, Sassano T, Guyenne P, et al.: Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. Br J Clin Pharmacol 1987, 24:465-472.
41. Redfield MM, Neumann A, Tajik AJ, et al.: Effect of long-acting oral felodipine and nifedipine on left ventricular contractility in patients with systemic hypertension: differentiation between reflex sympathetic and direct contractile responses [abstract]. J Am Coll Cardiol 1994, 23:348A.
42. Muiesan G, Agabiti-Rosei E, Romanelli G, et al.: Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Cardiol 1986, 57:44D-49D.
43. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol 1990, 66:779-785.
44. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988, 319:385-392.
45. Wenzel RR, Allegranza G, Binkeli C, et al.: Differential activation of cardiac and peripheral nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997, 29:1207-1214.
46. 2 receptor inhibition of the T-type calcium current in non-differential NG108-15 cells. J Biol Chem 1995, 270:1670-1674.
47. DeGasparo M, Bottari S, Levens N: Characteristics of angiotensin II receptors and their role in cell and organ physiology. In Hypertension: Pathology, Diagnosis, and Management, 2nd edn. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:1695-1720.
48. Billmann GE, Hamlin RL: The effects of mibefradil, a novel calcium channel antagonist, on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 1996, 277:1517-1526.
49. Mulder P, Richard V, Compagnon P, et al.: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997, 29:416-421.
50. Massie B: Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? J Am Coll Cardiol 1988, 12:547-548.
51. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
52. Cohn J, Levine T, Olivari M, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
53. Laragh JH: Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens 1995, 9:385-390.
54. Packer M, O'Connor CM, Ghali JK, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-14.
55. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987, 316:1429-1435.
56. Pitt B, Segal R, Martinez F, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747-752.
57. Packer M, Bristow M, Cohn J, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
58. Levine TB: The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol 1997, 20:320-326.